MLYSHIGH SIGNALFINANCIAL10-K

MLYS underwent a massive capital raise that tripled assets and stockholders' equity while improving operational efficiency and reducing losses.

The dramatic increase in stockholders' equity from $191M to $647M (+238%) indicates a significant financing event, likely an equity raise or strategic investment that substantially strengthened the company's financial position. This massive capital infusion provides MLYS with significantly more runway to fund their single product candidate lorundrostat through clinical trials, reducing near-term financial risk for this clinical-stage biotech company.

Comparing 2026-03-12 vs 2025-02-12View on EDGAR →
FINANCIAL ANALYSIS

MLYS experienced a transformational financial improvement with total assets growing 221% to $662M and stockholders' equity surging 238% to $647M, indicating a major capital raise. Despite this influx of capital, the company improved operational efficiency with R&D expenses declining 22% to $132M and net losses improving 13% to -$155M, while operating cash flow burn also improved 14% to -$142M. The combination of substantially increased financial resources and improved operational metrics signals stronger financial stability and extended runway for this single-asset biotech company.

FINANCIAL STATEMENT CHANGES
Stockholders Equity
Balance Sheet
+238.1%
$191.3M→$646.7M

Equity base grew 238.1% — retained earnings accumulation or equity issuance strengthening the balance sheet.

Current Assets
Balance Sheet
+222.1%
$205.4M→$661.4M

Current assets grew 222.1% — improving short-term liquidity or inventory/receivables build.

Total Assets
Balance Sheet
+221.4%
$205.9M→$661.8M

Asset base grew 221.4% — expansion through organic growth, acquisitions, or capital deployment.

Cash & Equivalents
Balance Sheet
+51.6%
$114.1M→$172.9M

Cash position surged 51.6% — strong cash generation or capital raise providing significant financial cushion.

R&D Expense
P&L
-21.7%
$168.6M→$132.0M

R&D spending cut 21.7% — could signal cost discipline or concerning reduction in innovation investment.

Operating Cash Flow
Cash Flow
+14.4%
-$166.3M→-$142.4M

Operating cash flow grew 14.4% — strong conversion of earnings to cash, healthy business fundamentals.

Net Income
P&L
+13%
-$177.8M→-$154.7M

Net income grew 13% — bottom-line growth signals improving overall business health.

Operating Income
P&L
+11.3%
-$192.4M→-$170.6M

Operating income improving — cost discipline or growing revenue base absorbing fixed costs.

LANGUAGE CHANGES
NEW — 2026-03-12
PRIOR — 2025-02-12
ADDED
(Exact name of registrant as specified in its charter) Delaware 84-1966887 (State or other jurisdiction of incorporation or organization) (I.R.S.
Our future performance at this time is entirely dependent on the success of our only product candidate, lorundrostat.
We heavily rely on our exclusive license agreement entered into in July 2020 (the Tanabe License) with Tanabe Pharma Corporation (Tanabe) to provide us with intellectual property rights to develop and commercialize lorundrostat.
We also depend on third party manufacturers for the production of lorundrostat.
All statements other than statements of historical facts contained in this Annual Report, including statements regarding our future results of operations and financial position, business strategy, research and development plans, the anticipated timing, costs, design, and conduct of our ongoing and planned preclinical studies and planned clinical trials for lorundrostat and any future product candidates, the timing and likelihood of regulatory filings and approvals for lorundrostat (including the anticipated timing of any U.S.
+7 more — sign up free →
REMOVED
(Exact name of registrant as specified in its charter) Delaware 2834 84-1966887 (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) (I.R.S.
Our future performance at this time is entirely dependent on the success of our only product candidate, lorundrostat, which is currently in clinical development and has not completed a pivotal trial.
We heavily rely on our exclusive license agreement entered into in July 2020 (Mitsubishi License) with Mitsubishi Tanabe Pharma Corporation (Mitsubishi Tanabe) to provide us with intellectual property rights to develop and commercialize lorundrostat.
These statements involve known and unknown risks, uncertainties, and other important factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements.
Our clinical-stage product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor (ASI) that we are developing for the treatment of cardiorenal conditions affected by dysregulated aldosterone, including hypertension, chronic kidney disease (CKD), and obstructive sleep apnea (OSA).
+7 more — sign up free →
MORE FINANCIAL SIGNALS
PNRGHIGHPNRG achieved exceptional profitability improvement with net income surging 2,21...
2026-04-16
BNAIHIGHBNAI underwent a dramatic reverse stock split that reduced share count by 86% wh...
2026-04-16
LAKEHIGHLAKE's financial performance deteriorated significantly with operating losses wo...
2026-04-16
NXXTHIGHNextNRG experienced massive financial deterioration with operating losses explod...
2026-04-16
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →